Literature DB >> 21484224

Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients.

Chingching Foocharoen1, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Ratanavadee Nanagara.   

Abstract

Skin tightness is a major clinical manifestation of systemic sclerosis (SSc). Importantly for both clinicians and patients, spontaneous regression of the fibrosis process has been documented. The purpose of this study is to identify the incidence and related clinical characteristics of spontaneous regression among Thai SSc patients. A historical cohort with 4 years of follow-up was performed among SSc patients over 15 years of age diagnosed with SSc between January 1, 2005 and December 31, 2006 in Khon Kaen, Thailand. The start date was the date of the first symptom and the end date was the date of the skin score ≤2. To estimate the respective probability of regression and to assess the associated factors, the Kaplan-Meier method and Cox regression analysis was used. One hundred seventeen cases of SSc were included with a female to male ratio of 1.5:1. Thirteen patients (11.1%) experienced regression. The incidence rate of spontaneous skin regression was 0.31 per 100 person-months and the average duration of SSc at the time of regression was 35.9±15.6 months (range, 15.7-60 months). The factors that negatively correlated with regression were (a) diffuse cutaneous type, (b) Raynaud's phenomenon, (c) esophageal dysmotility, and (d) colchicine treatment at onset with a respective hazard ratio (HR) of 0.19, 0.19, 0.26, and 0.20. By contrast, the factor that positively correlated with regression was active alveolitis with cyclophosphamide therapy at onset with an HR of 4.23 (95% CI, 1.23-14.10). After regression analysis, only Raynaud's phenomenon at onset and diffuse cutaneous type had a significantly negative correlation to regression. A spontaneous regression of the skin fibrosis process was not uncommon among Thai SSc patients. The factors suggesting a poor predictor for cutaneous manifestation were Raynaud's phenomenon, diffuse cutaneous type while early cyclophosphamide therapy might be related to a better skin outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21484224     DOI: 10.1007/s10067-011-1744-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  Outcome measures in rheumatologic clinical trials and systemic sclerosis.

Authors:  D E Furst
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

Review 2.  Outcome measurement in scleroderma clinical trials.

Authors:  J E Pope; N Bellamy
Journal:  Semin Arthritis Rheum       Date:  1993-08       Impact factor: 5.532

Review 3.  Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.

Authors:  C Sunderkötter; G Riemekasten
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

Review 4.  Scleroderma--demographics and survival.

Authors:  A J Silman
Journal:  J Rheumatol Suppl       Date:  1997-05

5.  Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982.

Authors:  V D Steen; C V Oddis; C G Conte; J Janoski; G Z Casterline; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-03

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  G A Knock; G Terenghi; C B Bunker; H A Bull; P M Dowd; J M Polak
Journal:  J Invest Dermatol       Date:  1993-07       Impact factor: 8.551

8.  Diffuse systemic sclerosis and related diseases in Thailand.

Authors:  S Panicheewa; S Chitrabamrung; O Verasertniyom; M Vanichaphantu; S O Kraisit; P Chiewsilp; M Vatanasuk
Journal:  Clin Rheumatol       Date:  1991-06       Impact factor: 2.980

9.  Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.

Authors:  Takashi Matsushita; Minoru Hasegawa; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

10.  Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.

Authors:  Sule Apras; Ihsan Ertenli; Zeynep Ozbalkan; Sedat Kiraz; M Akif Ozturk; Ibrahim C Haznedaroglu; Veli Cobankara; Salih Pay; Meral Calguneri
Journal:  Arthritis Rheum       Date:  2003-08
View more
  4 in total

Review 1.  Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.

Authors:  Michele Iudici; Serena Fasano; Daniela Iacono; Barbara Russo; Giovanna Cuomo; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2013-11-19       Impact factor: 2.980

2.  Recovery from severe dysphagia in systemic sclerosis - myositis overlap: a case report.

Authors:  Keith J Chinniah; Girish M Mody
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

3.  Renal pathology and clinical associations in systemic sclerosis: a historical cohort study.

Authors:  Pantipa Tonsawan; Komkid Talabthong; Anucha Puapairoj; Chingching Foocharoen
Journal:  Int J Gen Med       Date:  2019-09-02

4.  Development and validation of machine learning for early mortality in systemic sclerosis.

Authors:  Chingching Foocharoen; Wilaiphorn Thinkhamrop; Nathaphop Chaichaya; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Bandit Thinkhamrop
Journal:  Sci Rep       Date:  2022-10-13       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.